Isomorphic Labs, a DeepMind spinoff focusing on drug discovery, raised $600M led by Thrive to research treatments, including for cancer and immune disorders
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer.
Context & Ripple Effects
Before this financing, Isomorphic Labs had established a commercial route to market through AI-drug-discovery partnerships with Eli Lilly and Novartis, combining upfront payments with performance incentives.
The round became an early marker of investor conviction: related coverage later records a $2.1B Thrive-led follow-on financing, suggesting the company’s capital needs and ambitions expanded beyond an initial research buildout.
First-order effects
- Isomorphic Labs gains $600M to extend AI-enabled treatment research across cancer and immune disorders, while Thrive Capital becomes a major financial backer.
- The financing gives the DeepMind spinoff more runway to pursue its existing drug-discovery work alongside pharmaceutical partners.
Second-order effects
- The round strengthens Isomorphic Labs’ position when negotiating research priorities and downstream economics with drug-company collaborators, including the previously announced Lilly and Novartis relationships.
- Thrive’s lead investment gives other investors a concrete funding benchmark for AI drug-discovery companies that must finance both computational research and pharmaceutical development work.
Third-order effects
- If follow-on financings continue to concentrate around a small set of AI-biology companies, drug discovery may increasingly favor well-capitalized platform builders over narrowly scoped tool vendors.
- The later $2.1B round indicates that validation in this category may require successive large financings, making access to committed growth investors a structural advantage rather than a one-time boost.
The trend: AI drug discovery is moving toward capital-intensive platform companies that pair frontier-model capabilities with pharmaceutical partnerships and repeat financing rounds.